Skip to main content
Premium Trial:

Request an Annual Quote

New Products: WuXi's NextCode Analysis; Dana-Farber's Heme Panel; More

Premium

WuXi PharmaTech's Genome Center is now offering analysis services from NextCode Health, a bioinformatics company in Cambridge, Mass., which will provide population-scale genome analysis. NextCode will work with the WuXi Genome Center to process sequence data from WuXi's customers and produce a report discussing the medical implications.


The Dana-Farber Cancer Institute and the Brigham and Women's Cancer Center have a launched Rapid Heme Panel, a next-gen sequencing-based panel that analyzes alterations in 95 genes that are frequently associated with leukemias and myeloid disorders. The test has a turnaround time of five business days.


Enzymatics has launched Archer Assay Designer, a software platform to design custom primer panels to generate target-enriched libraries in order to identify gene fusions through next-gen sequencing. The software allows the user to search for genes and exons of interest.


Almac Group has launched a CLIA validated next-gen sequencing assay for P53 mutations. The test can be run on formalin-fixed paraffin-embedded samples and covers all coding regions and upstream regulatory regions of P53.


Swift Biosciences has launched an early access program for its next-generation sequencing-based TP53 Panel that covers all coding exons of the gene. The panel uses Swift's Accel-NGS Amplicon Panel technology and runs on Illumina's sequencing instruments. In addition, it is planning another panel using the Accel-NGS Ampliocn technology that will target over 200 clinically relevant cancer mutations.

The Scan

Purnell Choppin Dies

Purnell Choppin, a virologist who led the Howard Hughes Medical Institute, has died at 91, according to the Washington Post.

Effectiveness May Decline, Data From Israel Suggests

The New York Times reports that new Israeli data suggests a decline in Pfizer-BioNTech SARS-CoV-2 vaccine effectiveness against Delta variant infection, though protection against severe disease remains high.

To See Future Risk

Slate looks into the use of polygenic risk scores in embryo screening.

PLOS Papers on Methicillin-Resistant Staphylococcus, Bone Marrow Smear Sequencing, More

In PLOS this week: genomic analysis of methicillin-resistant Staphylococcus pseudintermedius, archived bone marrow sequencing, and more.